ӳ����ý

and the ӳ����ý of MIT and Harvard today announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development.

“Together with the ӳ����ý, we are simplifying the path to licensing CRISPR technology, which will make it more widely available to the global research and discovery community,” said Udit Batra, CEO, MilliporeSigma. “Through this agreement, we will make it easier for our customers to be successful in their research that shortens drug development timelines for previously untreatable diseases.”

ӳ����ý and MilliporeSigma share the goal of enabling all entities to apply the technology with a wider range of CRISPR tools. To streamline access for scientists, ӳ����ý institute will offer licenses to MilliporeSigma’s and ӳ����ý’s CRISPR IP portfolios to potential licensees for internal research uses and for commercial research tools and kits. Under the agreement, companies applying CRISPR in their research and development activities can license both sets of IP through ӳ����ý. The framework is designed to allow other key patent holders to participate in the future — either through this framework or via a third-party patent pool or collaboration — to further streamline non-exclusive access to key CRISPR technology.

“We believe that key CRISPR patent holders should come together to simplify and open up access, and this agreement is another example of a partnership that helps maximize and streamline access to these important scientific tools,” said Issi Rozen, Chief Business Officer of the ӳ����ý. “ӳ����ý already licenses CRISPR non-exclusively for all applications, with the exception of human therapeutics. We are actively working to ensure the widest and simplest possible access to key CRISPR intellectual property.”

The institutions worked together to develop a framework that (i) continues to provide non-exclusive access to ӳ����ý-controlled IP co-owned with its collaborators (including Harvard University, the Massachusetts Institute of Technology, New York Genome Center, New York University, The Rockefeller University, the University of Iowa Research Foundation, the University of Tokyo, the Whitehead Institute for Biomedical Research and others) and (ii) provides non-exclusive access to IP from MilliporeSigma, with certain limitations specific to the MilliporeSigma IP for creation of rodent models.

Features of the licensing framework:

• MilliporeSigma’s IP for CRISPR technology, offered under the portfolio brand, will become available royalty-free to non-profit academic institutions, non-profit business communities and governmental agencies for their internal research, consistent with the ӳ����ý’s long-standing practice and requirements.
• Licenses follow ӳ����ý’s and MilliporeSigma’s ethical licensing considerations, which exclude certain CRISPR technology applications, such as for any clinical human germline editing.
• Each entity can continue offering licenses independently, outside of this framework.
• In addition to IP from ӳ����ý and MilliporeSigma, this licensing framework includes certain ӳ����ý IP co-owned with multiple other institutions: Harvard University, the Massachusetts Institute of Technology, New York Genome Center, New York University, The Rockefeller University, the University of Iowa Research Foundation, the University of Tokyo, the Whitehead Institute for Biomedical Research and others.

ӳ����ý and MilliporeSigma have developed licensing guidelines that support research with genome editing under careful consideration of ethical and legal standards. The ӳ����ý outlines “institutional policies on IP licensing” on its website. MilliporeSigma’s parent company, Merck KGaA, Darmstadt, Germany, has established an independent, external to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has defined a clear operational taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.